Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Increases By 24.1%

Health Catalyst, Inc. (NASDAQ:HCAT) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 2,940,000 shares, an increase of 24.1% from the February 28th total of 2,370,000 shares. Based on an average daily volume of 807,300 shares, the short-interest ratio is currently 3.6 days. Approximately 5.0% of the shares of the stock are short sold.

Analyst Ratings Changes

HCAT has been the subject of several analyst reports. Stephens dropped their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Royal Bank of Canada dropped their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Thursday, February 27th. Wells Fargo & Company decreased their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Stifel Nicolaus cut their price target on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Stock Up 2.8 %

Shares of NASDAQ:HCAT traded up $0.12 during mid-day trading on Wednesday, hitting $4.45. 441,111 shares of the company traded hands, compared to its average volume of 614,976. The firm has a market cap of $312.44 million, a P/E ratio of -3.30 and a beta of 1.41. Health Catalyst has a 52-week low of $3.76 and a 52-week high of $9.24. The firm’s 50 day simple moving average is $4.96 and its 200 day simple moving average is $6.78. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Insider Transactions at Health Catalyst

In related news, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at $685,310.03. The trade was a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,530 shares of company stock valued at $299,572 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC grew its stake in shares of Health Catalyst by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock valued at $37,055,000 after acquiring an additional 944,631 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after buying an additional 195,525 shares during the last quarter. Daventry Group LP boosted its stake in Health Catalyst by 3.8% in the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock valued at $17,742,000 after acquiring an additional 91,878 shares during the period. Alyeska Investment Group L.P. raised its position in shares of Health Catalyst by 74.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after purchasing an additional 861,150 shares during the period. Finally, Kennedy Capital Management LLC lifted its stake in Health Catalyst by 42.7% in the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company’s stock valued at $13,369,000 after buying an additional 565,445 shares during the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.